Multiple orifice implantable heart valve and methods of implantation

Information

  • Patent Grant
  • 10245142
  • Patent Number
    10,245,142
  • Date Filed
    Thursday, May 28, 2015
    10 years ago
  • Date Issued
    Tuesday, April 2, 2019
    6 years ago
Abstract
A surgically implantable multiple orifice heart valve having a valve frame with at least two orifices, each of which can accommodate a tissue valve. The multiple orifice heart valve includes a stent frame having a first side, an opposite second side, and multiple orifices or opening, each of which extends from the first side to the second side of the stent frame and is adjacent to at least one of the other multiple orifices or openings.
Description
TECHNICAL FIELD

The present invention relates generally to devices and methods for repair of heart valves, and more particularly to prosthetic heart valves for use in replacement of the mitral valve.


BACKGROUND

One of the two atrio-ventricular valves in the heart is the mitral valve, which is located on the left side of the heart and which forms or defines a valve annulus and valve leaflets. The mitral valve is located between the left atrium and the left ventricle, and serves to direct oxygenated blood from the lungs through the left side of the heart and into the aorta for distribution to the body. As with other valves of the heart, the mitral valve is a passive structure in that it does not itself expend any energy and does not perform any active contractile function.


The mitral valve includes two moveable leaflets that open and close in response to differential pressures on either side of the valve. Ideally, the leaflets move apart from each other when the valve is in an open position, and meet or “coapt” when the valve is in a closed position. However, problems can develop with valves, which can generally be classified as either stenosis, in which a valve does not open properly, or insufficiency (also called regurgitation), in which a valve does not close properly. Stenosis and insufficiency may occur concomitantly in the same valve. The effects of valvular dysfunction vary, with mitral regurgitation or backflow typically having relatively severe physiological consequences to the patient. Regurgitation, along with other abnormalities of the mitral valve, can increase the workload placed on the heart. The severity of this increased stress on the heart and the patient, and the ability of the heart to adapt to it, determine the treatment options that are available for a particular patient. In some cases, medication can be sufficient to treat the patient, which is the preferred option when it is viable; however, in many cases, defective valves have to be repaired or completely replaced in order to adequately restore the function of the heart.


One situation where repair of a mitral valve is often viable is when the defects present in the valve are associated with dilation of the valve annulus, which not only prevents competence of the valve but also results in distortion of the normal shape of the valve orifice. Remodeling of the annulus is central to these types of reconstructive procedures on the mitral valve. When a mitral valve is repaired, the result is generally a reduction in the size of the posterior segment of the mitral valve annulus. As a part of the mitral valve repair, the involved segment of the annulus is diminished (i.e., constricted) so that the leaflets may coapt correctly on closing, and/or the annulus is stabilized to prevent post-operative dilatation from occurring. Either result is frequently achieved by the implantation of a prosthetic ring or band in the supra annular position. The purpose of the ring or band is to restrict, remodel and/or support the annulus to correct and/or prevent valvular insufficiency. Such repairs of the valve, when technically possible, can produce relatively good long-term results.


However, valve repair is sometimes either impossible, undesirable, or has failed, such as in cases where the problem is not related to dilation of the valve annulus, leaving valve replacement as the most viable option for improving operation of the mitral valve. The two general categories of valves that are used for mitral valve replacement are mechanical valves and bioprosthetic or tissue valves. A wide variety of mechanical valves are available that accommodate the blood flow requirements of the particular location where they will be implanted; however, the use of these mechanical devices in the body can increase the risk of clotting in the blood stream, which can lead to a heart attack or stroke. Thus, mechanical valve recipients must take anti-coagulant drugs for the rest of their lives to minimize the potential of blood clots. The use of tissue valves advantageously eliminates the need for such anti-coagulant drugs; however, tissue valves do not typically last as long as mechanical valves and may need to be replaced at some later point in the patient's life. To implant either mechanical or tissue valves, a surgical procedure is typically used that involves opening the patient's chest to access the mitral valve through the left atrium, and then implanting the new valve in position.


To simplify surgical procedures and reduce patient trauma, there has been a recent increased interest in minimally invasive and percutaneous replacement of cardiac valves. Such a replacement of a heart valve typically does not involve actual physical removal of the diseased or injured native heart valve, but instead includes delivery of a replacement valve in a compressed condition to the native valve site, where it is expanded. One example of such a replacement procedure for a pulmonary valve includes inserting a replacement pulmonary valve into a balloon catheter and delivering it percutaneously via the vascular system to the location of a failed pulmonary valve. There, the replacement valve is expanded by a balloon to compress the native valve leaflets against the right ventricular outflow tract, thereby anchoring and sealing the replacement valve. In the context of percutaneous pulmonary valve replacement, U.S. Patent Application Publication Nos. 2003/0199971 A1 and 2003/0199963 A1, both filed by Tower, et al., describe a valved segment of bovine jugular vein, mounted within an expandable stent, for use as a replacement pulmonary valve. As described in the articles: “Percutaneous Insertion of the Pulmonary Valve”, Bonhoeffer, et al., Journal of the American College of Cardiology 2002; 39: 1664-1669 and “Transcatheter Replacement of a Bovine Valve in Pulmonary Position”, Bonhoeffer, et al., Circulation 2000; 102: 813-816, a replacement pulmonary valve may be implanted to replace native pulmonary valves or prosthetic pulmonary valves located in valved conduits. Other implantables and implant delivery devices also are disclosed in published U.S. Patent Application Publication No. 2003/0036791 A1 and European Patent Application No. 1 057 460-A1.


The percutaneous valve implantation procedures described above typically involve the movement of a compressed valve through at least some portion of the vasculature of the patient to the delivery site, and are therefore particularly well-suited for implanting relatively small valves, such pulmonary valves or aortic valves. Because a replacement mitral valve is typically relatively large as compared to the portions of the anatomy through which it would need to travel to reach the region of the native mitral valve, the percutaneous valve implantation procedures described in the above journal articles may not be feasible for a mitral valve. However, there is a continued desire to be able to be able to improve mitral valve replacement devices and procedures to accommodate the physical structure of the heart without causing undue stress to the patient during the operation on the heart, such as providing devices and methods for replacing the mitral valve percutaneously.


SUMMARY

One embodiment of the invention is a surgically implantable multiple orifice heart valve having a valve frame with at least two orifices, each of which can accommodate a tissue valve. The outer peripheral shape of the valve frame can be modeled for implantation in the mitral valve position, and can therefore be generally circular, oval, or elliptical in shape, with at least two adjacent orifices or openings. The orifices in one embodiment are generally circular in shape, although they can have a different shape than circular, if desired. Each of the orifices within a single valve frame may have the same size and shape as each of the other orifices of that valve frame, or the orifices within a single valve frame can each have a different size and/or shape than the other orifices of that frame in order to adapt to the size and shape of the native valve opening.


A bi-leaflet valve, tri-leaflet valve, or differently configured valve can be mounted within each opening. Each of the individual valves are designed for generally simultaneous opening and closing of the multiple valves that are mounted in the same valve frame. That is, regardless of the leaflet structure provided, each of the heart valves should be oriented and designed so that all of the valves within a single valve frame can open and close at generally the same time within the heart cycle in response to changes in blood flow. In this way, the multiple valves function in generally the same manner as the native valve or as a single replacement valve in the patient. In particular, when the leaflets of both valves are in an open position, an internal passage is defined by each orifice through which blood can flow, and when the leaflets of both valves are in a closed position, the internal passages through the orifices do not allow for the flow of blood through the valves. With specific reference to the mitral valve, the leaflets of the valves of the multiple orifice heart valve will generally function in such a way that blood flows toward the left ventricle when the leaflets are in an open position, and so that blood is prevented from moving toward the left atrium when the leaflets are in a closed position.


It is also within the scope of the invention that the two or more orifices of a valve configuration used in a single valve opening in a patient can be independent such that they can move at least slightly relative to each other. That is, two or more separate orifice structures can be implanted into a single valve space in such a way that movement of the orifice structures relative to each other may be possible during and after implantation.


If a tri-leaflet valve is attached within any of the orifices, three commissure posts can extend from one side of the valve frame and be spaced from each other around each of the orifices. The commissure posts define the juncture between adjacent tissue and/or synthetic leaflets secured to the valve frame. Similar or different structures can be provided to extend from or otherwise be attached to the valve frame for other valve configurations (e.g. for bi-leaflet valves). In some embodiments, it is possible for one or more commissure posts to be shared by adjacent valve structures.


The valve frame is the structure of the multiple orifice heart valve that provides a means of fixing the prosthetic heart valve to the patient's native heart valve orifice tissue (e.g, native annulus or valvular rim) that is associated with the native heart valve being repaired or replaced. The valve frame includes a base portion around or over which a suture material (e.g., a cloth-like material) is disposed for suturing the prosthesis to heart tissue. The suture or cloth-like material portion may also cover any support structures, such as the commissure posts described above.


It is contemplated that the valve frames of the invention are initially implanted without any attached valve structures. The valves can subsequently be delivered in a minimally invasive manner to the orifices in the valve frame and attached via coalescent clips or other means.


Once the valve frame with attached valve structures (e.g., the prosthetic heart valve with multiple orifices, as described above) is implanted within the patient, the valve can be expected to function without problems for a period of time, and possibly as long as several years, without any noticeable issues. However, if deficiencies occur at any time after implantation in one or more of the valves of the multiple-valve structure, each deficient valve can potentially be replaced by percutaneously delivering a new valve via transcatheter implantation. Each of these individual valves would be relatively small as compared to the overall valve size that would be required for percutaneous implantation of a comparable mitral valve that fills the mitral valve space. In this way, the complications and risks involved with additional surgical intervention can be minimized or avoided. Another advantage of using multiple valves with a smaller size instead of one larger diameter valve is that the protrusions or other extending structures of the stent frame can be somewhat smaller. Thus, the protrusions will not extend as far into the ventricle when the device is implanted, thereby reducing the potential for obstruction or damage to the ventricle and/or the native valvular apparatus, such as chordae or papillary muscles.


The invention further includes a method of surgically implanting a multiple orifice valve assembly into the mitral valve area of a patient, then percutaneously delivering a replacement valve, such as a stented valve, to at least one of the orifices of the surgically implanted valve assembly. Each percutaneously delivered replacement valve can include features for proper orientation and positioning relative to the orifice of the surgically implanted heart valve. For one example, the percutaneously delivered valve can include a stent having docking features that are designed or selected to cooperate with features of the valve frame for secure anchoring of the elements relative to each other. Thus, it is within the scope of the invention for the valve frame of the multiple orifice valve assembly to have specific features or elements that allow for a certain type of engagement with a replacement valve having corresponding features. In that regard, the multiple orifice valve assembly and replacement valves can be provided as a kit. With any of the embodiments described above, the valve frames, stents, and other corresponding elements should be provided so that there is minimal interference with the functioning of an adjacent aortic valve. In addition, while many of the embodiments are shown and described as having two orifices in a valve frame, it is understood that the valve frames may include three or more orifices, which can help to accommodate the anatomies of patients having particularly large mitral openings.





BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further explained with reference to the appended Figures, wherein like structure is referred to by like numerals throughout the several views, and wherein:



FIG. 1 is a bottom perspective view of one embodiment of a valve frame in accordance with the invention;



FIG. 2 is a top plan view of the valve frame of FIG. 1 and illustrating exemplary valve leaflets in their closed positions;



FIG. 3 is a top plan view of another embodiment of a multiple-orifice valve assembly of the invention;



FIG. 4 is a top plan view of another embodiment of a multiple-orifice valve assembly of the invention;



FIG. 5 is a perspective view of a distal portion of a delivery system positioned relative to one orifice of a portion of a mitral valve replacement assembly;



FIG. 6 is a top schematic plan view of another embodiment of a multiple-orifice valve assembly of the invention;



FIG. 7 is a top plan view of another embodiment of a multiple-orifice valve assembly of the invention;



FIG. 8 is a top plan view of a tri-orifice valve assembly of the invention; and



FIG. 9 is a top plan view of another embodiment of a multiple-orifice valve assembly of the invention.





DETAILED DESCRIPTION

Referring now to the Figures, wherein the components are labeled with like numerals throughout the several Figures, and initially to FIGS. 1 and 2, one embodiment of a double orifice implantable heart valve 10 in accordance with the invention is illustrated. Although the heart valves of the invention, such as heart valve 10, are generally described herein as being used for mitral valve replacement, it is understood that many of the features of these heart valves can be used for valves in other areas of the heart. For example, the heart valves of the invention can be used in any area of the heart where it would be more advantageous to use multiple valves that are relatively small than to use a single valve that is relatively large. In any case, the heart valves of the invention desirably restore normal functioning of a cardiac valve, and are initially implanted using surgical techniques that include minimally invasive methods or more traditional open-heart surgical methods. Further, as used throughout this specification, a “prosthetic heart valve” or “heart valve” is intended to encompass bioprosthetic heart valves having leaflets made of biological material (e.g., harvested porcine valve leaflets, or bovine or equine pericardial leaflets), along with synthetic leaflet materials or other materials.


Heart valve 10 includes a valve frame 12 having a first orifice 14 and a second orifice 16. These orifices 14, 16 are illustrated to be generally the same size and shape as each other, and preferably are sized for attachment of a tissue valve within each of their interior portions. FIG. 2 illustrates the valve frame 12 with a first tri-leaflet valve 18 in its closed position within the first orifice 14 and a second tri-leaflet valve 20 in its closed position within the second orifice 16. This three-leaflet arrangement of valves 18, 20 is exemplary; alternative configurations include a bi-leaflet valve positioned in both of the orifices, and valves that are different from each other in each of the orifices (e.g., one of the orifices includes a three-leaflet valve while the other orifice includes a bi-leaflet valve). In any case, the multi-orifice valve configurations of the invention advantageously allow for replacement of only one of the valves if only one of the valves fails at some point after implantation (while at least one properly functioning valve remains operational), as will be described in further detail below. If such a valve replacement is performed, the specific rotational orientation of the valve leaflets within the orifice may or may not be a consideration.


Referring again to FIG. 1, the valve frame 12 has an outer periphery that is generally oval or elliptical in shape and has a first side 24 and an opposite second side 26. The valve frame 12 is generally shaped or modeled to match the valve space into which it will be surgically implanted. For example, if the valve frame 12 will be placed in the mitral valve space of a patient, characteristics of the specific mitral valve space into which it will be positioned can be taken into account. Thus, the valve frame 12 may have a generally planar surface on its first and second sides 24, 26, or it may have contours and shaping on one or both sides to match the anatomy of the patient. For example, it may be relatively saddle shaped. The valve frame 12 provides a means for fixing the double orifice implantable heart valve 10 to the patient's native heart valve orifice tissue (e.g., the native annulus or valvular rim) that is associated with the native heart valve being repaired or replaced. In particular, a surgical implantation technique can be employed whereby the heart is stopped (e.g., with the use of cardiopulmonary bypass) and opened, which is followed by optional surgical removal of damaged or diseased natural valve structure. The heart valve 10 can then be oriented within the native valvular area, with the valve frame 12 being seated against or at the native annulus or valvular rim. Sutures can then be used to affix the valve frame 12 to the natural tissue.


With the various multiple valve assemblies of the invention, it is desirable to maximize the overall area of the orifices relative to the frame size in order to minimize the obstruction to blood flow. Thus, it is preferable that the sizes of the structural components of the stent frame are minimized, while the desired structural strength of the frame is maintained.


The first and second orifices 14, 16 are spaced from each other across the width of the valve frame 12, and the spacing and exact orientation of the orifices 14, 16 can be selected to provide desired performance characteristics for the valve. For example, the orifices 14, 16 can be generally circular in shape and arranged relative to their valve frame 12 so that the center points of the orifices 14, 16 generally coincide with a central axis that runs across the width of the valve frame 12. However, it is understood that the orifices 14, 16 can be at least slightly offset relative to the central axis of the valve frame 12 and/or that they can be at least slightly offset relative to each other (e.g., FIG. 9 illustrates an alternative valve assembly including first and second orifices 14′, 16′ slightly offset relative to a central axis of valve frame 12′). The orifices 14, 16 can be at least slightly spaced from each other, as shown, thereby providing a central area of the valve frame 12 between the two orifices 14, 16. Preferably, the portions of the heart valve assembly 10 between the orifices is impermeable to blood flow to resist regurgitation. The illustrated space between the orifices 14, 16 is one exemplary configuration, and can be smaller or larger than shown. Alternatively, there may be no space between two adjacent orifices 14, 16. Longitudinal axes that extend through the orifices (generally in the direction of blood flow) can be generally parallel to each other such that the orifices and corresponding valves lie in the same plane. Alternatively, the longitudinal axes of the orifices may be at least slightly offset relative to each other so that the orifices are at least slightly tilted or tipped toward or away from each other within the valve frame (e.g., as shown in FIG. 9).


As discussed above, in the exemplary embodiment of FIGS. 1 and 2, the valve frame 12 includes two tri-leaflet valves 18, 20. In order to provide the structure for attachment of these valves, multiple commissure posts 28 extend from the first side 24 of the valve frame 12. In particular, three commissure posts 28 are positioned around each of the orifices 14, 16, where the posts 28 can be spaced generally evenly from each other around the orifices 14, 16, or they can be unevenly spaced, depending on the characteristics of its corresponding valve. The commissure posts can be rigid yet somewhat flexible structures, which can be covered with a cloth-like material. The commissure posts define the juncture between adjacent tissue or synthetic leaflets that are secured within an orifice.


The valves provided in the valve frames described herein may use a preserved bovine jugular vein of the type described in the above-cited Bonhoeffer, et al. and Tower, et al. references. However, other vessels or donor species may alternatively be used for various reasons. For example, in order to provide additional valve strength in the relatively high-pressure conditions that exist in the mitral valve area of the heart, pericardial valves, polymeric valves, or metallic valves may alternatively be used in a tricuspid or bicuspid leaflet configuration.



FIG. 3 illustrates another embodiment of a double orifice implantable heart valve 30, which includes two prosthetic valves 32, 34 surrounded by a valve frame 36. In this embodiment, valves 32, 34 can each include stent structures of the type used in areas of the heart that accommodate relatively small, circular valves, such as the pulmonic valve. The valve frame 36 may be a gasket or other member that surrounds the outermost periphery of the valves 32, 34 to provide for sealing against paravalvular leakage and to facilitate pannus in-growth for stabilization of the heart valve 30. The valve frame 36 also preferably provides enough structural strength to position and maintain the valves 32, 34 in their desired arrangement relative to each other. The frame 36 can be relatively rigid to prevent most or all movement of the valves 32, 34 relative to each other, or the frame 36 can be relatively flexible to allow at least some movement of the valves 32, 34 relative to each other.


Another embodiment of a double orifice implantable valve assembly 100 is shown in FIG. 6. Valve assembly 100 includes a frame 102 from which two pairs of commissure posts 104 extend. Each commissure post 104 is positioned with another commissure post 104 located across from it on generally the opposite side of the frame 102. Each pair of commissure posts 104 provides the attachment areas for a bi-leaflet valve, where the frame 102 illustrates a first bi-leaflet valve 106 and a second bi-leaflet valve 108. As shown, valves 106, 108 are attached directly to the frame 102 in such a way that they do not have their own frames or stents. The valves can thus contact each other at least slightly in the central area of the stent frame, as illustrated. Since there is no additional stent structure internal to the frame 102, the size of the valves can be maximized relative to the opening in the frame 102.


The individual valves of the double orifice implantable heart valves described herein are generally shown and described as being cylindrical in shape; however, a number of different stent shapes are also contemplated, such as valves that are oval or elliptical in shape. Another exemplary alternative configuration is illustrated in FIG. 4 with a double orifice implantable heart valve 50 that includes a first prosthetic valve 52 and a second prosthetic valve 54, both of which are surrounded by a valve frame or gasket 56. Each of these two valves 52, 54 has a curvilinear surface that can be designed to generally match the shape of the ends of the annulus of a mitral valve, and a generally flat or planar surface that results in more “squared off” corners where the flat surface meets the curvilinear surface. The flat surfaces of the valves 52, 54 are in contact with each other along at least a portion of their lengths at a central area 58. This arrangement provides for less gaps or openings between the individual valves in a multiple valve arrangement than when circular valves are used. The heart valve 10 of FIG. 1 may alternatively include orifices that are shaped similarly to the valves 52, 54 of this embodiment in order to utilize valves that are somewhat D-shaped.


Another exemplary configuration of an implantable heart valve assembly of the invention includes a valve frame having two or more individual valves having different sizes and/or shapes from each other. For example, one or both of the valves can be at least slightly elliptical, oval, D-shaped, square, or differently shaped in cross-section when in their expanded conditions. For another example, one of the valves within a valve frame can be at least slightly larger than the other valve or valves of that frame, which would correspond to the orifices in which they are attached. In some cases, the differently sized and/or shaped orifices can help to better adapt the multiple-orifice heart valve to the native valve opening. The shape of the valves can be designed and selected to provide a proper fit to the patient's anatomy.


Another exemplary multiple orifice valve assembly 120 is illustrated in FIG. 7. Valve assembly 120 includes a first valve 122 and a second adjacent valve 124, both of which are tri-leaflet valves positioned within a stent frame 126. Stent frame 126 includes a number of commissure posts extending from one of its surfaces that act as the attachment points for the leaflets of the valves 122, 124. In particular, the leaflets of valve 122 are attached at commissure posts 128, 130, 132, and the leaflets of valve 124 are attached at commissure posts 132, 134, 136. Thus, the relatively central stent post 132 is shared by both of the valves 122, 124, thereby providing a relatively large orifice size inside the stent frame 126 with minimal obstructions to blood flow. A similar configuration can alternatively be used with two bi-leaflet valves in a single stent frame, where one of the commissure posts of the assembly is common to both valves. In yet another alternative embodiment, a stent assembly may include one bi-leaflet and one tri-leaflet valve, where both of the valves share one common commissure post.


Other valve assembly arrangements can include more than two valves within a single stent frame, as is contemplated by the present invention. For one example, three valves 150, 152, 154 are illustrated within a stent frame 156 in FIG. 8. The valves 150, 152, 154 are shown as having an intermediate stent or strut portion between each two adjacent valves; however, any of the other features described herein relative to stent assemblies with two valves can also be utilized in stent frames with three or more valves. Such multiple valve assemblies can include bi-leaflet valves, tri-leaflet valves, combinations of bi- and tri-leaflet valves that do not include intermediate strut portions, and the like.


Once a valve frame of the invention having attached valve structures (e.g., one of the prosthetic heart valve with multiple orifices described above) is implanted within the patient, the valve can function for a period of time with no noticeable issues. However, if deficiencies occur at any time after implantation in one or more of the valves of the multiple-valve structure, each deficient valve can be replaced by percutaneously delivering a new valve via transcatheter implantation. The invention further includes a method of surgically implanting a multiple orifice valve assembly into the mitral valve area of a patient, then percutaneously delivering a replacement valve to at least one of the orifices of the surgically implanted valve assembly. Each of these individual valves would be relatively small as compared to the overall valve size that would be required for percutaneous implantation of a comparable mitral valve that fills the mitral valve space, thereby better facilitating percutaneous implantation through a variety of access sites. The replacement valve can be a stented valve that includes an outer stent structure to which a valve structure is attached.



FIG. 5 illustrates a distal portion of an exemplary delivery system 70 as it is delivering a replacement stented valve 72 (shown schematically as only a stent of the valve) to a double orifice heart valve 80 that is depicted by two adjacent heart valves 74, 76. Heart valves 74, 76 are the two orifices of the double orifice heart valve 80 of the invention. The device or structure that attaches these valves to each other is gasket or frame 78. That is, the heart valves 74, 76 are intended to represent the two orifices of a single structure 80 that would previously been implanted into a patient, where the single structure could have been implanted to replace a mitral valve, for example. FIG. 5 represents the situation where some failure or malfunction of the leaflets of heart valve 74 has occurred, thereby necessitating a replacement of that heart valve. In accordance with the invention, it is possible to replace only this valve 74 of the two-valve system with a replacement stented valve 72, although it may be desirable or necessary to replace both valves 74, 76 with new replacement stented valves. The valve replacement procedure can advantageously be accomplished using a percutaneous valve delivery system.


In order to reduce potential stresses on the valve frames described herein and to reduce potential stresses on the associated annulus, it is also possible to provide multiple orifice structures that can move at least slightly relative to each other within a single native opening. In particular, the valves may be moveable relative to a defined plane and/or may be moveable to be positioned closer or further from each other during and after implantation. In such an embodiment, the stent frames can be made of flexible materials, such as metals, (e.g., Nitinol), polymers, or tissue-based materials.


The stented valves used to replace a deficient valve using the methods of the invention can correspond generally to a stent of the type described in the above-cited Tower, et al. and Bonhoeffer et al. references, for example, although it is understood that a wide variety of stent configurations can be used in accordance with the invention. The replacement stented valves may include a stent structure that is fabricated of platinum, stainless steel, Nitinol, an alloy of the type commercially available under the trade designation MP35N, or other biocompatible metal. The replacement stented valves may alternatively be fabricated using wire stock as described in the above-cited Tower, et al. applications, or the stented valves may be produced by machining or laser cutting the stent from a metal tube, as is commonly employed in the manufacturing of stents. The number of wires, the positioning of such wires, and various other features of the stents can vary considerably from that shown in the figures. In another alternative, the valves used to replace a deficient valve may be stentless valves.


In any case, the replacement stented valves used in the methods of the invention are preferably compressible to a relatively small diameter for insertion into a patient, but are also at least slightly expandable from this compressed condition to a larger diameter when positioned in a desired location in the patient. It is further preferable that the process of compressing the stented valves does not permanently deform the stent in such a way that expansion thereof would be difficult or impossible.


Any of the stent assemblies discussed herein can further include structures that provide a fixation function for securing the stent assembly in its desired location relative to the orifice of a previously implanted heart valve. For example, the stent assembly can include hooks, barbs, or the like that attach to a structure of a valve orifice upon deployment of the stent assembly.


A portion of an exemplary system that can be used to implant a stented valve of the types described above includes an elongated balloon catheter having an inflatable balloon that is connected for fluid communication with a lumen that extends through the length of the catheter. The lumen provides for inflation and deflation of the balloon with a fluid, such as a radio-opaque fluid, during the process of deploying a stented valve within a patient. The delivery system may include a thin guide wire that extends generally along the length of the catheter, which may be used in a conventional manner to guide the catheter to its desired implant location. When the components of the system are positioned relative to the orifice of a patient, a balloon may be inflated to thereby expand the stent to the desired size relative to the orifice in which it will be positioned. After such stent expansion is complete, the balloon can be deflated and the system can then be withdrawn from the patient.


It is further contemplated that two or more percutaneous valves can be simultaneously or sequentially delivered to a multiple orifice stent using a delivery system that has multiple balloons. For example, if both valves of a double-orifice valve are to be replaced at the same time, a delivery system having two balloons can be used to deliver both valves simultaneously.


The replacement heart valves, along with the multiple-orifice implantable heart valves of the present invention may be positioned within the desired area of the heart via entry in a number of different ways. In one example, the valves may be inserted transatrially, where entry may be done either percutaneously or in a minimally invasive technique on a beating heart in which access is through the side of the heart, or even through a standard open heart valve replacement procedure using heart-lung bypass and sternotomy where the described device would be used as an alternative to the standard replacement. In another example, the valves may be inserted transapically, where entry again may be done either percutaneously or in a minimally invasive technique on a beating heart in which access is through the side of the heart. In yet another example, the valves may be inserted transeptally, where entry can be done percutaneously, such as via the venous system into the right atrium and across a small hole in the septum to enter the left atrium. In yet another example, the valves may be inserted transfemorally through the arterial system. It is also possible that the delivery approaches may include balloons that would be used to facilitate the crossing of the mitral valve, thereby avoiding entanglement in the mitral apparatus.


It is also contemplated that the stented valves of the present invention are self-expanding such that pressure is required to maintain the valve in its compressed condition, and removal of such pressure will allow these stented valves to expand to their desired size. In these cases, the delivery system will be somewhat different than that described above relative to stents that are not self-expanding, and will instead include a system that only requires removal of external pressure (e.g., a compressive sheath) to allow the stented valves to expand, such as is the case with the delivery of stent grafts for aneurysms in the ascending aorta. These systems may also incorporate means for recapturing and/or repositioning the stented valve, if desired. In any case, it may be desirable to measure the mitral valve area with some type of spacer prior to installing the actual stent assembly in the heart of the patient.


The stented valves may further include a means of facilitating orientation of the assembly relative to the orifice in which they will be implanted, which can be particularly advantageous in cases where the stented valves include asymmetric features and configurations that must be properly oriented relative to the anatomy of the patient. To that end, the stented valves may include portions with materials that are opaque when viewed with various imaging techniques, such as echogenic coatings and radiopaque metals and polymers. Additionally or alternatively, the material used to fabricate the stent itself may be highly visible when using certain imaging techniques so that the user has a clear visibility of the orientation of the device prior to and during deployment.


The present invention has now been described with reference to several embodiments thereof. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made in the embodiments described without departing from the scope of the invention. Thus, the scope of the present invention should not be limited to the structures described herein.

Claims
  • 1. A heart valve assembly for implantation in a body lumen, the heart valve assembly comprising: a percutaneously implantable valve frame comprising an outer periphery having both a first side and an opposite second side, wherein the first side is an upper side of the valve frame and the second side is a lower surface of the valve frame; further wherein the valve frame has an outer shape that is compatible with a shape of a mitral valve;at least one opening extending through the valve frame from the first side to the second side, the at least one opening including a first opening;wherein the first opening is defined by an inner frame surrounded by the valve frame, and further wherein a perimeter shape of the first opening differs from a perimeter shape of the valve frame, and further wherein the first opening is offset with respect to a central axis of the valve frame; anda tissue valve disposed within the first opening, the tissue valve has a curvilinear surface and a generally flat surface collectively forming a substantially D-shape matching at least a portion of the annulus of the mitral valve.
  • 2. The heart valve assembly of claim 1, wherein the valve frame has a structural strength capable of surgical implantation into a patient.
  • 3. The heart valve assembly of claim 1, wherein the valve frame is a gasket that surrounds the outermost periphery of the tissue valve to provide for sealing against paravalvular leakage and to facilitate pannus in-growth for stabilization of the heart valve assembly.
  • 4. The heart valve assembly of claim 1, wherein one portion of the D-shape is planar and is in contact with an inner planar surface of the first opening.
  • 5. The heart valve assembly of claim 1, wherein the curvilinear surface of the D-shape is in contact with an inner curvilinear surface of the first opening.
  • 6. The heart valve assembly of claim 1, further comprising at least two commissure posts extending from the first side of the valve frame and adjacent to the first opening, wherein the tissue valve is coupled to the at least two commissure posts.
  • 7. The heart valve assembly of claim 1, wherein the at least one opening further includes a second opening apart from the first opening.
  • 8. The heart valve assembly of claim 7, further comprising a second tissue valve disposed within the second opening.
  • 9. The heart valve assembly of claim 7, wherein the first opening and the second opening are offset with respect to each other.
  • 10. A heart valve assembly for implantation in a body lumen, the heart valve assembly comprising: a percutaneously implantable valve frame comprising an outer periphery having both a first side and an opposite second side, wherein the first side is an upper side of the valve frame and the second side is a lower surface of the valve frame; further wherein the valve frame has an outer shape that is compatible with a shape of a mitral valve;a first opening and a second opening; each of the first and second openings extending through the valve frame from the first side to the second side;wherein the first opening is defined by an inner frame surrounded by the valve frame, and further wherein a perimeter shape of the first opening differs from a perimeter shape of the valve frame, and further wherein the first opening and the second opening are offset with respect to a central axis of the valve frame; anda first tissue valve disposed within the first opening.
  • 11. The heart valve assembly of claim 10, wherein the first opening and the second opening are offset with respect to each other.
  • 12. The heart valve assembly of claim 10, wherein the first tissue valve has a curvilinear surface and a generally flat surface collectively forming a substantially D-shape matching at least a portion of the annulus of the mitral valve.
  • 13. The heart valve assembly of claim 10, further comprising a second tissue valve disposed in the second opening.
CROSS-REFERENCE TO RELATED APPLICATION

The present application is a Continuation of and claims priority to U.S. patent application Ser. No. 13/860,779, filed Apr. 11, 2013; which is a Continuation of U.S. patent application Ser. No. 12/364,246, filed Feb. 2, 2009, now U.S. Pat. No. 8,430,927, which claims priority to U.S. Provisional Application No. 61/123,337, filed Apr. 8, 2008, and titled “Double Orifice Implantable Heart Valve”, the entire contents of which is incorporated herein by reference in its entirety.

US Referenced Citations (636)
Number Name Date Kind
3334629 Cohn Aug 1967 A
3409013 Berry Nov 1968 A
3540431 Mobin-Uddin Nov 1970 A
3587115 Shiley Jun 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4265694 Boretos May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4425908 Simon Jan 1984 A
4470157 Love Sep 1984 A
4501030 Lane Feb 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4681908 Broderick et al. Jul 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4777951 Cribier et al. Oct 1988 A
4781716 Richelsoph Nov 1988 A
4787899 Lazarus Nov 1988 A
4796629 Grayzel Jan 1989 A
4797901 Baykut Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4856516 Hillstead Aug 1989 A
4872874 Taheri Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4902291 Kolff Feb 1990 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4954126 Wallsten Sep 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002559 Tower Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5061273 Yock Oct 1991 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5135539 Carpentier Aug 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5217483 Tower Jul 1993 A
5232445 Bonzel Aug 1993 A
5272909 Nguyen et al. Dec 1993 A
5295958 Shturman Mar 1994 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum et al. Jul 1994 A
5350398 Pavcnik et al. Sep 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5415633 Lazarus et al. May 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5449384 Johnson Sep 1995 A
5480424 Cox Jan 1996 A
5489294 McVenes et al. Feb 1996 A
5489297 Duran Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5575818 Pinchuk Nov 1996 A
5580922 Park et al. Dec 1996 A
5591195 Taheri et al. Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5645559 Hachtman et al. Jul 1997 A
5665115 Cragg Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5695498 Tower Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5746709 Rom et al. May 1998 A
5749890 Shaknovich May 1998 A
5766151 Valley et al. Jun 1998 A
5782809 Umeno et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824041 Lenker Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824061 Quijano et al. Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5851232 Lois Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5860996 Tower Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876448 Thompson et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5906619 Olson et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5913842 Boyd et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6022370 Tower Feb 2000 A
6027525 Suh et al. Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6042589 Marianne Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV Mar 2000 A
6051104 Jang Apr 2000 A
6059809 Amor et al. May 2000 A
6110201 Quijano et al. Aug 2000 A
6146366 Schachar Nov 2000 A
6159239 Greenhalgh Dec 2000 A
6162208 Hipps Dec 2000 A
6162245 Jayaraman Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6218662 Tchakarov et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6248116 Chevilon Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolia et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6309382 Garrison et al. Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6338735 Stevens Jan 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6352708 Duran et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6605112 Moll et al. Aug 2003 B1
6613077 Gilligan et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6656213 Solem Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6692513 Streeter et al. Feb 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6719789 Cox Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6786925 Schoon Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6797002 Spence Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830575 Stenzel et al. Dec 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof Dec 2004 B1
6846325 Liddicoat Jan 2005 B2
6866650 Stevens Mar 2005 B2
6872223 Roberts Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890330 Streeter et al. May 2005 B2
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908481 Cribier Jun 2005 B2
6913600 Valley et al. Jul 2005 B2
6929653 Streeter Aug 2005 B2
6936066 Palmaz et al. Aug 2005 B2
6939365 Fogarty et al. Sep 2005 B1
6951571 Srivastava Oct 2005 B1
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin et al. Dec 2005 B2
6986742 Hart et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6991649 Sievers Jan 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7097659 Woolfson et al. Aug 2006 B2
7101396 Artof et al. Sep 2006 B2
7105016 Shui et al. Sep 2006 B2
7105020 Greenberg et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7128759 Osborne et al. Oct 2006 B2
7147663 Berg et al. Dec 2006 B1
7153324 Case et al. Dec 2006 B2
7160319 Chouinard et al. Jan 2007 B2
7175656 Khairkhahan Feb 2007 B2
7179290 Cao Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201761 Woolfson et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7252682 Seguin Aug 2007 B2
7300457 Palmaz Nov 2007 B2
7300463 Liddicoat Nov 2007 B2
7316706 Bloom et al. Jan 2008 B2
7329278 Seguin Feb 2008 B2
7335218 Wilson et al. Feb 2008 B2
7338520 Bailey et al. Mar 2008 B2
7374571 Pease et al. May 2008 B2
7377938 Sarac et al. May 2008 B2
7381218 Shreck Jun 2008 B2
7384411 Condado Jun 2008 B1
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470284 Lambrecht et al. Dec 2008 B2
7481838 Carpentier et al. Jan 2009 B2
7527646 Rahdert et al. May 2009 B2
7544206 Cohn et al. Jun 2009 B2
7547322 Sarac et al. Jun 2009 B2
7556646 Yang et al. Jul 2009 B2
7682390 Seguin Mar 2010 B2
7780726 Seguin Aug 2010 B2
7806919 Bloom et al. Oct 2010 B2
7871435 Carpentier Jan 2011 B2
20010002445 Vesely Mar 2001 A1
20010001314 Davison et al. May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010011189 Drasler et al. Aug 2001 A1
20010021872 Bailey Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20020010508 Chobotov Jan 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020058993 Landau et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020072789 Hackett et al. Jun 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020103533 Langberg et al. Aug 2002 A1
20020107565 Greenhalgh Aug 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020133183 Lentz et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023300 Bailey et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Bonhoeffer et al. Feb 2003 A1
20030036795 Andersen et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030109924 Cribier Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030139804 Hankh et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030191519 Lombardi et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199963 Tower et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030212410 Stenzel et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040088045 Cox May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040092989 Wilson et al. May 2004 A1
20040093005 Durcan May 2004 A1
20040093060 Sequin et al. May 2004 A1
20040093075 Kuehn May 2004 A1
20040097788 Mourles et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122516 Fogarty Jun 2004 A1
20040127979 Wilson Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040167573 Williamson Aug 2004 A1
20040167620 Ortiz Aug 2004 A1
20040186563 Iobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040210240 Saint Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040225353 McGuckin, Jr. Nov 2004 A1
20040225354 Allen Nov 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050010246 Streeter Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050027348 Case et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050038509 Ashe Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto Mar 2005 A1
20050049696 Siess Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060029 Le Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075712 Biancucci Apr 2005 A1
20050075717 Nguyen Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050075730 Myers Apr 2005 A1
20050075731 Artof Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050096568 Kato May 2005 A1
20050096692 Linder et al. May 2005 A1
20050096724 Stenzel et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050113910 Paniagua May 2005 A1
20050119688 Berheim Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137686 Salahieh Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137692 Haug Jun 2005 A1
20050137695 Salahieh Jun 2005 A1
20050137701 Salahieh Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh Jun 2005 A1
20050148997 Valley et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203618 Sharkawy Sep 2005 A1
20050222674 Paine Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240263 Fogarty et al. Oct 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004469 Sokel Jan 2006 A1
20060009841 McGuckin et al. Jan 2006 A1
20060020327 Lashinski Jan 2006 A1
20060030885 Hyde Feb 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058775 Stevens et al. Mar 2006 A1
20060089711 Dolan Apr 2006 A1
20060100685 Seguin et al. May 2006 A1
20060116757 Lashinski et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060167474 Bloom et al. Jul 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia Aug 2006 A1
20060206192 Tower et al. Sep 2006 A1
20060206202 Bonhoefer et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060247763 Slater Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271175 Woolfson et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060276882 Case et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070005131 Taylor Jan 2007 A1
20070010878 Raffiee et al. Jan 2007 A1
20070016286 Case et al. Jan 2007 A1
20070027518 Herrmann et al. Feb 2007 A1
20070027533 Douk Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043431 Melsheimer Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070073392 Heyninck-Janitz Mar 2007 A1
20070078509 Lotfy et al. Apr 2007 A1
20070078510 Ryan Apr 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093869 Bloom et al. Apr 2007 A1
20070100439 Cangialosi May 2007 A1
20070100440 Figulla May 2007 A1
20070100449 O'Neil et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070156233 Kapadia Jul 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070162113 Sharkawy et al. Jul 2007 A1
20070185513 Woolfson et al. Aug 2007 A1
20070203391 Bloom et al. Aug 2007 A1
20070225681 House Sep 2007 A1
20070232898 Huynh et al. Oct 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070233238 Huynh et al. Oct 2007 A1
20070238979 Huynh et al. Oct 2007 A1
20070239254 Marchand et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239266 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239271 Nguyen Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244544 Birdsall et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244553 Rafiee et al. Oct 2007 A1
20070244554 Rafiee et al. Oct 2007 A1
20070244555 Rafiee et al. Oct 2007 A1
20070244556 Rafiee et al. Oct 2007 A1
20070244557 Rafiee et al. Oct 2007 A1
20070250160 Rafiee Oct 2007 A1
20070255394 Ryan Nov 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070288000 Bonan Dec 2007 A1
20080004696 Vesely Jan 2008 A1
20080009940 Cribier Jan 2008 A1
20080015671 Bonhoeffer Jan 2008 A1
20080021552 Gabbay Jan 2008 A1
20080048656 Tan Feb 2008 A1
20080065001 Marchand et al. Mar 2008 A1
20080065206 Liddicoat Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080077234 Styrc Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080133003 Seguin et al. Jun 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147105 Wilson et al. Jun 2008 A1
20080147180 Ghione et al. Jun 2008 A1
20080147181 Ghione et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080154355 Benichow et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080183273 Mesana Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080215143 Seguin et al. Sep 2008 A1
20080215144 Ryan et al. Sep 2008 A1
20080228254 Ryan Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080234797 Stryc Sep 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080255651 Dwork Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080262593 Ryan et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090012600 Styrc et al. Jan 2009 A1
20090048656 Wen Feb 2009 A1
20090054976 Tuval et al. Feb 2009 A1
20090069886 Suri et al. Mar 2009 A1
20090069887 Righini et al. Mar 2009 A1
20090069889 Suri et al. Mar 2009 A1
20090082858 Nugent et al. Mar 2009 A1
20090085900 Weiner Apr 2009 A1
20090099653 Suri et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090164004 Cohn Jun 2009 A1
20090164006 Seguin et al. Jun 2009 A1
20090171447 VonSeggesser et al. Jul 2009 A1
20090192585 Bloom et al. Jul 2009 A1
20090192586 Tabor et al. Jul 2009 A1
20090192591 Ryan et al. Jul 2009 A1
20090198316 Laske et al. Aug 2009 A1
20090216310 Straubinger et al. Aug 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090216313 Straubinger et al. Aug 2009 A1
20090222082 Lock et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240264 Tuval et al. Sep 2009 A1
20090240320 Tuval Sep 2009 A1
20090287296 Manasse Nov 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100030328 Seguin et al. Feb 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100036485 Seguin Feb 2010 A1
20100069852 Kelley Mar 2010 A1
20100094411 Tuval et al. Apr 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100145439 Seguin et al. Jun 2010 A1
20100152840 Seguin et al. Jun 2010 A1
20100161045 Righini Jun 2010 A1
20100198346 Keogh et al. Aug 2010 A1
20100234940 Dolan Sep 2010 A1
20100256723 Murray Oct 2010 A1
Foreign Referenced Citations (51)
Number Date Country
2007-100074433 Aug 2007 CN
3640745 Jun 1987 DE
195 32 846 Mar 1997 DE
195 46 692 Jun 1997 DE
195 46 692 Jun 1997 DE
198 57 887 Jul 2000 DE
199 07 646 Aug 2000 DE
100 10 074 Oct 2001 DE
100 49 812 Apr 2002 DE
100 49 813 Apr 2002 DE
100 49 815 Apr 2002 DE
1057460 Jun 2000 EP
1255510 Nov 2002 EP
1469797 Nov 2005 EP
2788217 Dec 1999 FR
2815844 May 2000 FR
2056023 Mar 1981 GB
2433700 Dec 2007 GB
1271508 Nov 1986 SU
9529640 Nov 1995 WO
0044313 Aug 2000 WO
0047136 Aug 2000 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
0164137 Sep 2001 WO
0203892 Jan 2002 WO
0222054 Mar 2002 WO
0236048 May 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
04019825 Mar 2004 WO
04089250 Oct 2004 WO
04103223 Dec 2004 WO
05004753 Jan 2005 WO
05046528 May 2005 WO
05087139 Sep 2005 WO
06026371 Mar 2006 WO
06091163 Aug 2006 WO
08047354 Apr 2008 WO
08138584 Nov 2008 WO
08150529 Dec 2008 WO
09002548 Dec 2008 WO
09029199 Mar 2009 WO
09042196 Apr 2009 WO
09045338 Apr 2009 WO
09061389 May 2009 WO
09091509 Jul 2009 WO
09111241 Sep 2009 WO
Non-Patent Literature Citations (40)
Entry
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J. (1992) 13:704-708.
Babaliaros, et al., “State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair,” Cardiology 2007; 107:87-96.
Bailey, “Percutaneous Expandable Prosthetic Valves,” In: Topol EJ, ed. Textbook of Interventional Cardiology. vol. II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276.
Block, et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, vol. 7 (2005) pp. 108-113.
Bonhoeffer, et al, “Percutaneous Insertion of the Pulmonary Valve,” Journal of the American College of Cardiology (United States), May 15, 2002, pp. 1664-1669.
Bonhoeffer, et al, “Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction,” Lancet (England), Oct. 21, 2000, pp. 1403-1405.
Bonhoeffer, et al, “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation (United States), Aug. 15, 2000, pp. 813-816.
Boudjemline, et al, “Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals,” Circulation (United States), Mar. 16, 2004, 109, p. e161.
Boudjemline, et al, “Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Mar. 2004, pp. BR61-BR66.
Boudjemline, et al, “Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: A Hybrid Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Apr. 2005, pp. 831-837.
Boudjemline, et al, “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study,” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-BR116.
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal 22, Sep. 2001, p. 630.
Boudjemline, et al, “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs,” European Heart Journal (England), Jul. 2002, pp. 1045-1049.
Boudjemline, et al, “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study,” Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087.
Boudjemline, et al, “Percutaneous Valve Insertion: A New Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742.
Boudjemline, et al, “Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits,” European Heart Journal 22, Sep. 2001, p. 355.
Boudjemline, et al, “Steps Toward Percutaneous Aortic Valve Replacement,” Circulation (United States), Feb. 12, 2002, pp. 775-778.
Boudjemline, et al, “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93.
Boudjemline, et al, “Transcatheter Reconstruction of the Right Heart,” Cardiology in the Young (England), Jun. 2003, pp. 308-311.
Coats, et al, “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543.
Cribier, A. et al, “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description,” Circulation (2002) 3006-3008.
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15 (2006) 123-129.
Hanzel, et al., “Complications of percutaneous aortic valve replacement: experience with the Criber-Edwards™ percutaneous heart valve,” EuroIntervention Supplements (2006), 1 (Supplement A) A3-A8.
Huber, et al., “Do Valved Stents Compromise Coronary Flow?” Eur. J. Cardiothorac. Surg. 2004;25:754-759.
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408.
Khambadkone, et al, “Percutaneous Implantation of Pulmonary Valves,” Expert Review of Cardiovascular Therapy (England), Nov. 2003, pp. 541-548.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375.
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Impact of Morphology on Case Selection,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-642-IV-643.
Lutter, et al, “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776.
Lutter, et al, “Percutaneous Valve Replacement: Current State and Future Prospects,” Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206.
Ma, Ling, et al., “Double-crowned valved stents for off-pump mitral valve replacement,” European Journal of Cardio Thoracic Surgery, 28:194-198, 2005.
Medtech Insight, “New Frontiers in Heart Valve Disease,” vol. 7, No. 8 (2005).
Palacios, “Percutaneous Valve Replacement and Repair, Fiction or Reality?” Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663.
Pelton et al., “Medical Uses of Nitinol,” Materials Science Forum vols. 327-328, pp. 63-70 (2000).
Ruiz, “Transcathether Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, vol. 26, No. 3 (2005).
Saliba, et al, “Treatment of Obstructions of Prosthetic Conduits by Percutaneous Implantation of Stents,” Archives des Maldies du Coeur et des Vaisseaux (France), 1999, pp. 591-596.
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation (2006), 113;842-850.
Stassano et al., “Mid-term results of the valve-on-valve technique for bioprosthetic failure,” Eur. J. Cardiothorac. Surg. 2000; 18:453-457.
Pavcnik et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Techol. 2000, vol. 9, pp. 287-292.
Related Publications (1)
Number Date Country
20160278916 A1 Sep 2016 US
Provisional Applications (1)
Number Date Country
61123337 Apr 2008 US
Continuations (2)
Number Date Country
Parent 13860779 Apr 2013 US
Child 14723930 US
Parent 12364246 Feb 2009 US
Child 13860779 US